Anti-human MSLN antibody and MSLN-targeting immune effector cell
AssigneeHrain Biotechnology Co., Ltd.
InventorsFei Huang, Tao Peng, Xuemei Zou, Pinglei Liu, Dachun Liu, Hui Huang
Life of this patent
Estimating the term…
Abstract
The present invention provides an anti-human MSLN-specific antibody and an MSLN-targeting immune effector cell. Also provided is an MSLN-targeting chimeric antigen receptor modified T-cell prepared using the antibody and a use thereof.
Claims18
An antibody or antigen binding fragment thereof specifically binding to human MSLN, which comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain and the light chain variable domain comprise:
- heavy chain CDR1 as shown in SEQ ID NO:
- 7, heavy chain CDR2 as shown in SEQ ID NO:
- 8, and heavy chain CDR3 as shown in SEQ ID NO:
- 9;
- and light chain CDR1 as shown in SEQ ID NO:
- 10, light chain CDR2 as shown in SEQ ID NO:
- 11, and light chain CDR3 shown in SEQ ID NO:
- 12.
An anti-human MSLN chimeric antigen receptor, which comprises an extracellular region, a transmembrane region and an intracellular region, wherein the extracellular region comprises an antigen binding region, and the antigen binding region comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain and the light chain variable domain comprise:
- heavy chain CDR1 as shown in SEQ ID NO:
- 7, heavy chain CDR2 as shown in SEQ ID NO:
- 8, and heavy chain CDR3 as shown in SEQ ID NO:
- 9;
- and light chain CDR1 as shown in SEQ ID NO:
- 10, light chain CDR2 as shown in SEQ ID NO:
- 11, and light chain CDR3 shown in SEQ ID NO:
- 12.
A method of treating a cancer and/or stimulating immune function in a patient with a cancer, comprising administering to the patient a therapeutically effective amount of an antibody or antigen binding fragment thereof specifically binding to human MSLN, an anti-human MSLN chimeric antigen receptor, or a modified immune effector cell,
- wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain and the light chain variable domain comprise:
- heavy chain CDR1 as shown in SEQ ID NO:
- 7, heavy chain CDR2 as shown in SEQ ID NO:
- 8, and heavy chain CDR3 as shown in SEQ ID NO:
- 9;
- and light chain CDR1 as shown in SEQ ID NO:
- 10, light chain CDR2 as shown in SEQ ID NO:
- 11, and light chain CDR3 shown in SEQ ID NO:
- 12,
- the anti-human MSLN chimeric antigen receptor, comprises an extracellular region, a transmembrane region and an intracellular region, wherein the extracellular region comprises an antigen binding region, and the antigen binding region comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain and the light chain variable domain comprise:
- heavy chain CDR1 as shown in SEQ ID NO:
- 7, heavy chain CDR2 as shown in SEQ ID NO:
- 8, and heavy chain CDR3 as shown in SEQ ID NO:
- 9;
- and light chain CDR1 as shown in SEQ ID NO:
- 10, light chain CDR2 as shown in SEQ ID NO:
- 11, and light chain CDR3 shown in SEQ ID NO:
- 12, and
- the modified immune effector cell expresses the anti-human MSLN chimeric antigen receptor.
Dependencies are inferred from the claim text.